Browsing by Author "Keskin O."

Now showing 1 - 5 of 5
  • No Thumbnail Available
    Item
    The reliability and validity of Turkish version of Childhood Asthma Control Test
    (2012) Sekerel B.E.; Soyer O.U.; Keskin O.; Uzuner N.; Yazicioglu M.; Kiliç M.; Artaç H.; Ozmen S.; Can D.; Zeyrek D.; Cokugras H.; Canitez Y.; Aydogan M.; Kuyucu S.; Inal A.; Gurkan F.; Orhan F.; Yilmaz O.; Boz A.B.; Tahan F.; Cevit O.
    Introduction: The reliability and validity of Turkish version of Childhood Asthma Control Test (C-ACT). Purpose: The management of asthma is an important as well as difficult issue of physician's daily practice particularly in busy clinical settings. C-ACT was created to identify asthma control levels in children aged 4-11 years. Our aim was to evaluate the reliability, validity and responsiveness of C-ACT in a Turkish sample of children with asthma. Method: In this multicenter study, 368 children were enrolled. C-ACT was completed every month by parents and patients who were evaluated in 3 visits within 2 month intervals. At each visit, physicians interpret the control level and decided for the treatment step as established in GINA guidelines. Results: The internal consistency reliability of the Turkish version of C-ACT (C-ACT1 to C-ACT5) was found to be 0.82, 0.83, 0.82, 0.82 and 0.80, respectively (reliability statistics, Cronbach's alpha). Test-retest reliability was 0.71. There was significant correlation between C-ACT and physician's assessment of asthma control at visit 1 (r = 0.65, P <0.001). Conclusions: Turkish version of C-ACT is an accurate and reliable tool to evaluate asthma control in children aged 4-11 years. Its widespread use may facilitate appropriate assessment of asthma control and may lead to decrease the number of uncontrolled patients. © Springer Science+Business Media B.V. 2011.
  • No Thumbnail Available
    Item
    Clinical features and accompanying findings of Pseudo-Bartter Syndrome in cystic fibrosis
    (John Wiley and Sons Inc., 2020) Sismanlar Eyuboglu T.; Dogru D.; Çakır E.; Cobanoglu N.; Pekcan S.; Cinel G.; Yalçın E.; Kiper N.; Sen V.; Selimoglu Sen H.; Ercan O.; Keskin O.; Bilgic Eltan S.; Alshadfan L.; Yazan H.; Altıntas D.U.; Sasihuseyinoglu A.S.; Sapan N.; Cekic S.; Cokugraş H.; Kılınc A.A.; Ramaslı Gursoy T.; Aslan A.T.; Bingol A.; Başaran A.E.; Ozdemir A.; Kose M.; Hangul M.; Emiralioglu N.; Tugcu G.; Yuksel H.; Yılmaz O.; Orhan F.; Gayretli Aydın Z.G.; Topal E.; Tamay Z.; Suleyman A.; Can D.; Bal C.M.; Caltepe G.; Ozcelik U.
    Background: Pseudo-Bartter syndrome (PBS) is a rare complication of cystic fibrosis (CF) and there are limited data in the literature about it. We aimed to compare clinical features and accompanying findings of patients with PBS in a large patient population. Methods: The data were collected from the Cystic Fibrosis Registry of Turkey where 1170 CF patients were recorded in 2017. Clinical features, diagnostic test results, colonization status, complications, and genetic test results were compared in patients with and without PBS. Results: Totally 1170 patients were recorded into the registry in 2017 and 120 (10%) of them had PBS. The mean age of diagnosis and current age of patients were significantly younger and newborn screening positivity was lower in patients with PBS (P <.001). There were no differences between the groups in terms of colonization status, mean z-scores of weight, height, BMI, and mean FEV1 percentage. Types of genetic mutations did not differ between the two groups. Accompanying complications were more frequent in patients without PBS. Conclusion: PBS was detected as the most common complication in the registry. It could be due to warm weather conditions of our country. It is usually seen in younger ages regardless of mutation phenotype and it could be a clue for early diagnosis of CF. © 2020 Wiley Periodicals, Inc.
  • No Thumbnail Available
    Item
    The success of the Cystic Fibrosis Registry of Turkey for improvement of patient care
    (John Wiley and Sons Inc, 2022) Asfuroglu P.; Sismanlar Eyuboglu T.; Aslan A.T.; Gursoy T.R.; Emiralioglu N.; Yalcin E.; Kiper N.; Sen V.; Sen H.S.; Altintas D.U.; Ozcan D.; Kilinc A.A.; Cokugras H.; Baskan A.K.; Yazan H.; Erenberk U.; Dogan G.; Unal G.; Yilmaz A.I.; Keskin O.; Arik E.; Kucukosmanoglu E.; Irmak I.; Damadoglu E.; Ozturk G.K.; Gulen F.; Basaran A.E.; Bingol A.; Cekic S.; Sapan N.; Kilic G.; Harmanci K.; Kose M.; Ozdemir A.; Tugcu G.D.; Polat S.E.; Hangul M.; Ozcan G.; Aydin Z.G.G.; Yuksel H.; Topal E.; Ozdogan S.; Caltepe G.; Suleyman A.; Can D.; Ekren P.K.; Bal C.M.; Kilic M.; Cinel G.; Cobanoglu N.; Pekcan S.; Cakir E.; Ozcelik U.; Dogru D.
    Background: Cystic fibrosis (CF) registries play an essential role in improving disease outcomes of people with CF. This study aimed to evaluate the association of newly established CF registry system in Turkey on follow-up, clinical, growth, treatment, and complications of people with this disease. Methods: Age at diagnosis, current age, sex, z-scores of weight, height and body mass index (BMI), neonatal screening results, pulmonary function tests, history of meconium ileus, medications, presence of microorganisms, and follow-up were evaluated and compared to data of people with CF represented in both 2017 and 2019 registry data. Results: There were 1170 people with CF in 2017 and 1637 in 2019 CF registry. Eight hundred and fourteen people were registered in both 2017 and 2019 of whom z-scores of heights and BMI were significantly higher in 2019 (p = 0.002, p =0.039, respectively). Inhaled hypertonic saline, bronchodilator, and azithromycin usages were significantly higher in 2019 (p =0.001, p = 0.001, p = 0.003, respectively). The percent predicted of forced expiratory volume in 1 sec and forced vital capacity were similar in 2017 and 2019 (88% and 89.5%, p = 0.248 and 84.5% and 87%, p =0.332, respectively). Liver diseases and osteoporosis were significantly higher, and pseudo-Bartter syndrome (PBS) was significantly lower in 2019 (p = 0.011, p = 0.001, p = 0.001, respectively). Conclusions: The z-scores of height and BMI were higher, the use of medications that protect and improve lung functions was higher and incidence of PBS was lower in 2019. It was predicted that registry system increased the care of people with CF regarding their follow-up. The widespread use of national CF registry system across the country may be beneficial for the follow-up of people with CF. © 2022 Wiley Periodicals LLC.
  • No Thumbnail Available
    Item
    Gastrostomy in Hospitalized Patients with Acute Stroke: “NöroTek” Turkey Point Prevalence Study Subgroup Analysis; [Hastanede Yatan Akut İnmeli Hastalarda Gastrostomi: “NöroTek” Türkiye Nokta Prevalans Çalışması Alt Grup Analizi]
    (Turkish Neurosurgical Society, 2022) Topçuoğlu M.A.; Özdemir A.Ö.; Aykaç Ö.; Milanoğlu A.; Gökçe M.; Bavli S.; Çabalar M.; Yayla V.; Erdoğan H.A.; Özkul A.; Güneş A.; Değirmenci B.; Aluçlu U.; Kozak H.H.; Güngör L.; Erdoğan M.; Acar Z.Ö.; Cenikli U.; Kablan Y.; Yılmaz A.; Genç H.; Nazliel B.; Çağlayan H.B.; Gencer E.S.; Ay H.; Demirbaş H.; Akdoğan Ö.; Emre U.; Yıldız Ö.K.; Bolayır A.; Demir T.; Tanrıverdi Z.; Tekan Ü.Y.; Akpınar Ç.K.; Özkan E.; İlik F.; Şirin H.; Güler A.; Önder H.; Bektaş H.; Öcek L.; Bakar M.; Ongun N.; Krespi Y.; Işıkay C.T.; Aslanbaba E.; Sorgun M.; Gürkaş E.; Karadeli H.H.; Midi İ.; İlgezdi İ.; Bilgiç A.B.; Akyol Ş.; Epçeliden M.T.; Atmaca M.M.; Kurşun O.; Keskin O.; Şirinocak P.B.; Baydemir R.; Akçakoyunlu M.; Öztürk Ş.; Özel T.; Ünal A.; Dora B.; Yürekli V.A.; Arlıer Z.; Eren A.; Yılmaz A.; Kısabay A.; Acar B.; Baştan B.; Niflioğlu B.; Güven B.; Kaya D.; Afşar N.; Yazıcı D.; Aytaç E.; Yaka E.; Toplutaş E.; Değirmenci E.; İnce F.B.; Büyükşerbetçi G.; Aydın İ.; Çetiner M.; Şen M.; Turgut N.; Kale N.; Çoban E.; Yeşilot N.; Ekizoğlu E.; Kizek Ö.; Birgili Ö.; Yevgi R.; Kunt R.; Giray S.; Akkaş S.Y.; Şenadım S.; Yoldaş T.; Asil T.; Duman T.; Atasoy T.; Çınar B.P.; Demir T.; Can U.; Ünsal Y.Ö.; Eşkut N.; Aslan Y.; Baş D.F.; Şener U.; Yılmaz Z.; Bozdoğan Z.; Alioğlu Z.; Arsava E.M.
    Objective: Nutritional status assessment, dysphagia evaluation and enteral feeding decision are important determinants of prognosis in acute neurovascular diseases. Materials and Methods: NöroTek is a point prevalence study conducted with the participation of 87 hospitals spread across all health sub regions of Turkey conducted on 10-May-2018 (World Stroke Awareness Day). A total of 972 hospitalized neurovascular patients [female: 53%, age: 69±14; acute ischemic stroke in 845; intracerebral hematoma (ICH) in 119 and post-resuscitation encephalopathy (PRE) in 8] with complete data were included in this sub-study. Results: Gastrostomy was inserted in 10.7% of the patients with ischemic stroke, 10.1% of the patients with ICH and in 50% of the patients with PRE. Independent predictors of percutaneous endoscopic gastrostomy (PEG) administration were The National Institutes of Health Stroke Scale score at admission [exp (β): 1.09 95% confidence interval (CI): 1.05-1.14, per point] in ischemic stroke; and mechanical ventilation in ischemic [exp (β): 6.18 (95% CI: 3.16-12.09)] and hemorrhagic strokes [exp (β): 26.48 (95% CI: 1.36-515.8)]. PEG was found to be a significant negative indicator of favorable (modified Rankin’s scale score 0-2) functional outcome [exp (β): 0.032 (95% CI: 0.004-0.251)] but not of in-hospital mortality [exp (β): 1.731 (95% CI: 0.785-3.829)]. Nutritional and swallowing assessments were performed in approximately two-thirds of patients. Of the nutritional assessments 69% and 76% of dysphagia assessments were completed within the first 2 days. Tube feeding was performed in 39% of the patients. In 83.5% of them, tube was inserted in the first 2 days; 28% of the patients with feeding tube had PEG later. Conclusion: The NöroTek study provided the first reliable and large-scale data on key quality metrics of nutrition practice in acute stroke in Turkey. In terms of being economical and accurate it makes sense to use the point prevalence method. © 2022 by Turkish Neurological Society.
  • No Thumbnail Available
    Item
    Acute Stroke Management in Türkiye: Intravenous Tissue Plasminogen Activator and Thrombectomy NöroTek: Türkiye Neurology Single Day Study; [Türkiye’de Akut İnme Yönetimi: IV tPA ve Trombektomi NöroTek: Türkiye Nöroloji Tek Gün Çalışması]
    (Turkish Neurosurgical Society, 2023) Topçuoğlu M.A.; Özdemir A.Ö.; Arsava E.M.; Güneş A.; Aykaç Ö.; Gencer E.S.; Çabalar M.; Yayla V.; Erdoğan H.A.; Erdoğan M.; Acar Z.Ö.; Giray S.; Kablan Y.; Tanrıverdi Z.; Tekan Ü.Y.; Asil T.; Akpınar Ç.K.; Yürekli V.A.; Acar B.; Şirin H.; Güler A.; Baydemir R.; Akçakoyunlu M.; Öcek L.; Çetiner M.; Nazlıel B.; Çağlayan H.B.; Ongun N.; Eren A.; Arlıer Z.; Cenikli U.; Gökçe M.; Bavli S.; Yaka E.; Özkul A.; Değirmenci B.; Aluçlu U.; Işıkay C.T.; Aslanbaba E.; Sorgun M.; Aytaç E.; Ay H.; Kunt R.; Şenadım S.; Ünsal Y.Ö.; Eşkut N.; Alioğlu Z.; Yılmaz A.; Genç H.; Yılmaz A.; Milanoğlu A.; Gürkaş E.; Değirmenci E.; Bektaş H.; İlgezdi İ.; Bilgiç A.B.; Akyol Ş.; Güngör L.; Kale N.; Çoban E.; Yeşilot N.; Ekizoğlu E.; Kizek Ö.; Kurşun O.; Yıldız Ö.K.; Bolayır A.; Kısabay A.; Baştan B.; Niflioğlu B.; Güven B.; Kaya D.; Afşar N.; Yazıcı D.; Toplutaş E.; Özkan E.; İlik F.; İnce F.B.; Büyükşerbetçi G.; Önder H.; Karadeli H.H.; Kozak H.H.; Demirbaş H.; Midi İ.; Aydın İ.; Epçeliden M.T.; Atmaca M.M.; Bakar M.; Şen M.; Turgut N.; Keskin O.; Akdoğan Ö.; Emre U.; Bilgili Ö.; Şirinocak P.B.; Yevgi R.; Akkaş S.Y.; Yoldaş T.; Duman T.; Özel T.; Ünal A.; Dora B.; Atasoy T.; Çınar B.P.; Demir T.; Demir T.; Can U.; Aslan Y.; Baş D.F.; Şener U.; Yılmaz Z.; Bozdoğan Z.; Özdemir G.; Krespi Y.; Öztürk Ş.
    Objective: To reveal the profile and practice in patients with acute stroke who received intravenous tissue plasminogen activator (IV tPA) and/or neuro-interventional therapy in Türkiye. Materials and Methods: On World Stroke Awareness Day, May 10, 2018, 1,790 patients hospitalized in 87 neurology units spread over 30 health regions were evaluated retrospectively and prospectively. Results: Intravenous tPA was administered to 12% of 859 cases of acute ischemic stroke in 45 units participating in the study. In the same period, 8.3% of the cases received neurointerventional treatment. The rate of good prognosis [modified Rankin score (mRS) 0–2] at discharge was 46% in 83 patients who received only IV tPA [age: 67 ± 12 years; National Institutes of Health Stroke Scale (NIHSS): 12 ± 6; hospital stay, 24 ± 29 days]; 35% in 51 patients who underwent thrombectomy (MT) alone (age: 64 ± 13 years; NIHSS: 14.1 ± 6.5; length of hospital stay, 33 ± 31 days), 19% in those who received combined treatment (age: 66 ± 14 years; NIHSS: 15.6 ± 5.4; length of hospital stay, 26 ± 35 days), and 56% of 695 patients who did not receive treatment for revascularization (age: 70 ± 13 years; NIHSS: 7.6 ± 7.2; length of hospital stay, 21 ± 28 days). The symptom-to-door time was 87 ± 53 minutes in the IV treatment group and 200 ± 26 minutes in the neurointerventional group. The average door-to-needle time was 66 ± 49 minutes in the IV tPA group. In the neurothrombectomy group, the door-to-groin time was 103 ± 90 minutes, and the TICI 2b-3 rate was 70.3%. In 103 patients who received IV tPA, the discharge mRS 0–2 was 41%, while the rate of mRS 0–1 was 28%. In 71 patients who underwent neurothrombectomy, the mRS 0–2 was 31% and mRS 0–1 was 18%. The door-to-groin time was approximately 30 minutes longer if IV tPA was received (125 ± 107 and 95 ± 83 minutes, respectively). Symptomatic bleeding rates were 4.8% in IV recipients, 17.6% among those who received only MT, and 15% in combined therapy. Globally, the hemorrhage rate was 6.8% in patients receiving IV tPA and 16.9% in MT. Conclusion: IV thrombolytic and neurointerventional treatment applications in acute ischemic stroke in Türkiye can provide the anticipated results. Heterogeneity has begun to be reduced in our country with the dissemination of the system indicated by the “Directive on Health Services to be Provided to Patients with Acute Stroke.”. © Copyright 2023 by the Turkish Neurological Society / Turkish Journal of Neurology published by Galenos Publishing House.